Please login to the form below

Not currently logged in
Email:
Password:

Quintiles signs local bioanalytical deal for South Korea

Partners with Seoul-based contract research organisation BioCore

Quintiles has signed a partnership agreement that will allow it to complement its global bioanalytical service with a local offering for South Korea and other Asian markets.

The two-year deal with BioCore will see the Seoul-based contract research organisation (CRO) provide its services to Quintiles exclusively for a two-year period.

Jenny Zhang, vice president and general manager of Asia Laboratories at Quintiles, said: “Gathering high-quality bioanalytical data early in development is crucial to biopharma companies making informed decisions that increase their probability of success in expensive later-stage trials.

“This partnership with BioCore is part of our plan to add local capabilities as needed to augment Quintiles' GLP (Good Laboratory Practice) bioanalytics lab and CAP (College of American Pathologists)-accredited network of central labs.”

Quintiles has been operating in South Korea since 2000 but the firm's global bioanalytical capability only began picking up speed with its 2011 acquisition of Advion BioServices.

Advion, which is now called Advion Bioanalytical Labs and operates as a Quintiles company, will continue to serve global customers but Quintiles will now offer BioCore as a local bioanalytical lab for Asia.

BioCore is South Korea's largest provider of bioanalytical liquid chromatography-tandem mass spectrometry services and in 2005 it became South Korea's first GLP-complaint centralised bioanalytical CRO.

Hyung Sik Choie, BioCore president and CEO, said: “This partnership expands BioCore's bioanalysis and bioequivalence studies beyond Korea to other Asian countries. Our vision is to become more global; this alliance advances our efforts to achieve that vision.” 

South Korea's pharmaceutical market has seen consistent double-digit growth over the last five years and consultants IMS Health consider it to be the fastest-growing developed country.

As a result of this, and the high level of industry interest in the region, the region has seen a number of CRO deals in South Korea and its neighbours from the likes of INC Research, Parexel and PRA.

10th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
C+D

C+D has been informing, supporting and championing community pharmacy for more than 150 years. As an award-winning multi-media publisher we...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....

Infographics